Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker TRDA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | Todd Foley | 3.89M | 9.9% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | Luke Evnin | 3.89M | 9.9% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | Ansbert Gadicke | 3.89M | 9.9% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM BioVentures 2018 LLC | 1.94M | 5.0% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM BioVentures 2018 GP LLC | 1.91M | 4.9% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM Asset Management Investors BV2018 LLC | 35,735 | 0.1% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM Bioventures 2018 (B), L.P. | 96,232 | 0.2% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM Bioventures 2018, L.P. | 1.81M | 4.7% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM BioVentures 2014 LLC | 1.94M | 5.0% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM BioVentures 2014 GP LLC | 1.88M | 4.8% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM Asset Management Investors BV2014 LLC | 60,722 | 0.2% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM BioVentures 2014 (B), L.P. | 117,667 | 0.3% | SCHEDULE 13D/A ↗ |
| Sep 10, 2026 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 1.76M | 4.5% | SCHEDULE 13D/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | Chen Yu | 1.06M | 2.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | TCG Crossover Fund I, L.P. | 1.06M | 2.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | TCG Crossover GP I, LLC | 1.06M | 2.7% | SCHEDULE 13G/A ↗ |
| Nov 25, 2025 | SCHEDULE 13G | TRDA Entrada Therapeutics, Inc. | Chen Yu | 1.92M | 5.0% | SCHEDULE 13G ↗ |
| Nov 25, 2025 | SCHEDULE 13G | TRDA Entrada Therapeutics, Inc. | TCG Crossover Fund I, L.P. | 1.92M | 5.0% | SCHEDULE 13G ↗ |
| Nov 25, 2025 | SCHEDULE 13G | TRDA Entrada Therapeutics, Inc. | TCG Crossover GP I, LLC | 1.92M | 5.0% | SCHEDULE 13G ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | Scott M. Rocklage | 2.96M | 7.8% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | Kush Parmar | 4.12M | 10.8% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | Andrew J. Schwab | 4.06M | 10.6% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | 5AM Opportunities I (GP), LLC | 0 | 2.9% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | 5AM Opportunities I, L.P. | 1.09M | 2.9% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | 5AM Partners V, LLC | 2.96M | 7.8% | SCHEDULE 13D/A ↗ |
| Nov 18, 2025 | SCHEDULE 13D/A (amended) | TRDA Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. | 2.96M | 7.8% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | T. Rowe Price Associates, Inc. | 360,526 | 0.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | Janus Henderson Group PLC | 1.52M | 4.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | T. Rowe Price Associates, Inc. | 2.57M | 6.8% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 1.88M | 5.0% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | Janus Henderson Group PLC | 2.12M | 5.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G | TRDA Entrada Therapeutics, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 1.88M | 5.0% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | TRDA Entrada Therapeutics, Inc. | Janus Henderson Group PLC | 2.08M | 5.6% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | Roche Holding Ltd | 2.57M | 6.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | TRDA Entrada Therapeutics, Inc. | Roche Finance Ltd | 2.57M | 6.9% | SCHEDULE 13G/A ↗ |
| Feb 4, 2025 | SCHEDULE 13G | TRDA Entrada Therapeutics, Inc. | BlackRock, Inc. | 1.97M | 5.3% | SCHEDULE 13G ↗ |
36 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 9:55 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances